What Is Mounjaro and What Class Does It Belong To
Mounjaro is the brand name for tirzepatide, a prescription injectable medication developed by Eli Lilly and Company. It was first approved by the U.S. Food and Drug Administration in May 2022 for improving blood sugar control in adults with type 2 diabetes, and later for chronic weight management. The drug works by activating both the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, which slows gastric emptying and reduces appetite. Mounjaro is not a GPL1 drug; it is a dual GIP and GLP-1 receptor agonist, which distinguishes it from single GLP-1 receptor agonist medications like semaglutide. For background on GLP-1 drugs and their market, see this overview from Forbes.
The active ingredient tirzepatide is a 39-amino acid linear peptide that mimics the action of natural incretin hormones. Because it targets two receptors instead of one, it is classified as a dual agonist rather than a GPL1-only compound. Eli Lilly markets Mounjaro in multiple dosage strengths delivered through a prefilled pen device. In clinical trials, participants using the highest dose lost an average of over 20 percent of their initial body weight, a result that positioned Mounjaro among the most effective anti-obesity medications available at the time of the data release. The FDA label explicitly describes tirzepatide as a GIP receptor agonist and GLP-1 receptor agonist, not a GPL1-only therapy.
Is Mounjaro a GPL1 Drug or a Dual Agonist
The term GPL1 refers specifically to glucagon-like peptide-1 receptor agonists, a class that includes drugs such as liraglutide and semaglutide. Mounjaro does not fit that single-class definition because its mechanism involves both GIP and GLP-1 pathways. Regulatory documents filed with the U.S. Securities and Exchange Commission by Eli Lilly describe tirzepatide as a dual GIP and GLP-1 receptor co-agonist, which is a distinct pharmacological category. This dual action is the reason Mounjaro is not classified as a GPL1 drug in official prescribing information.
In the competitive landscape, Mounjaro is often compared to GPL1 drugs because they share overlapping indications for type 2 diabetes and weight loss. However, the dual mechanism gives Mounjaro a different clinical profile, with trials showing greater average weight reduction than some GPL1-only treatments. The distinction matters for payers, providers, and patients evaluating treatment options. Eli Lilly has filed patents covering the dual-agonist formulation, reinforcing that the company positions Mounjaro as a separate class from traditional GPL1 therapies. The company's investor presentations and SEC filings detail how Mounjaro's mechanism differs from single GLP-1 receptor agonists.
Regulatory Status, Market Position, and Key Facts
The FDA approved Mounjaro for type 2 diabetes in 2022 and expanded the indication for chronic weight management in adults with obesity or overweight conditions in late 2023. The approval was based on randomized controlled trials that measured changes in body weight and glycemic markers. As of the latest public data, Mounjaro is one of the highest-revenue products for Eli Lilly, reflecting strong demand for both diabetes and weight management therapies. The drug is administered once weekly, and dose escalation follows a specific schedule to reduce gastrointestinal side effects. The FDA approval letters and label information are publicly available on the agency's website.
Eli Lilly is the sole manufacturer of Mounjaro, and the company has been expanding production capacity to meet global demand. In recent earnings reports, management has described Mounjaro as